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A B S T R A C T  
 
Chemotherapy-induced mucositis is a side effect of chemotherapy that often occurs in patients 
with solid tumors and lymphoma. Oral mucositis can affect nutritional status and the risk of 
infection, both local and systemic. Antioxidant Vitamin E is beneficial for the prevention and 
therapy of both oral and gastrointestinal mucositis. Aim: To determine the effect of vitamin E 
therapy on the incidence of oral mucositis in non-Hodgkin lymphoma (NHL) patients receiving 
chemotherapy. Methods: This is a single blind experimental study in 62 NHL patients undergoing 
chemotherapy who meet the inclusion criteria. Patients who met the inclusion criteria were 
randomly divided into 2 groups, namely 31 patients (treatment group) received vitamin E 400 mg 
/ IU per day for 7 days and 31 patients in the placebo group. The incidence and grade of oral 
mucositis were observed on day 7. Statistical analysis used Chi Square and Mann Whitney test 
according to the data type. Results: a total of 67% NHL patients were male, most of whom were 
over 46 years of age and as many as 50% of patients used chemotherapy regimens RCHOP and 
CHOP. There was an incidence of oral mucositis in 35% in the placebo group and 12.9% in the 
treated group (p = 0.038). In the placebo group there were 4.8% of patients with grade 2 and 3 
oral mucositis, which were not found in the therapy group. Conclusion:  treatment with vitamin 
E in NHL patients undergoing chemotherapy can prevent chemotherapy-induced oral mucositis 
and prevent its severity. 
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I N T R O D U C T I O N  
Chemotherapy-induced mucositis is an 
erythematous and ulcerative lesion of the oral 
mucosa observed in patients with cancer 
treated with chemotherapy, and / or with 
radiation therapy. Oral mucositis lesions are 
often very painful and can affect nutrition and 
oral hygiene and can increase the risk of 
developing both local and systemic infections. 
Mucositis can also affect other areas of the 
digestive tract; for example, gastrointestinal 
(GI) mucositis which can manifest as diarrhea. 
Thus, it is clear that the effect of mucositis is 
very significant on the quality of life of patients. 
Likewise, the presence of mucositis often 
requires limiting the dose of cancer therapy. [1,2] 
One study reported the incidence of 
oral mucositis in 303 of 599 patients (51%) with 
solid tumors or lymphoma who received 
chemotherapy.[25] Oral mucositis developed in 
22% of 1236 chemotherapy cycles, whereas GI 
mucositis occurred in 7% of chemotherapy 
cycles.[25] The incidence of mucositis is also 
influenced by the dose of chemotherapy. In 
hematopoietic cell transplant patients who 
receive high doses of chemotherapy, the 
incidence of mucositis is around 75-80%. [3,4]  
Chemotherapy-induced mucositis 
causes significant pain which can affect 
nutritional intake, oral hygiene and quality of 
life. Infections associated with oral mucositis 
lesions can lead to life-threatening systemic 
infections. Moderate to severe chemotherapy-
induced mucositis correlated with infection-
related mortality. In patients with solid tumors 
or lymphoma who received chemotherapy and 
developed mucositis, the degree of infection 
during the cycle was two times higher and was 
directly proportional to its severity compared 
with the group without mucositis. Infection-
related deaths during chemotherapy cycles are 
more common in patients with oral or GI 
mucositis. Likewise, the mean duration of stay 
during chemotherapy was significantly longer 
in patients with mucositis. The incidence of 
chemotherapy dose reduction in subsequent 
cycles was two times higher in patients with 
mucositis than without mucositis.[5] 
The pain from mucositis causes eating 
disorders by mouth, so it is often necessary to 
get nutrition via gastrostomy or intravenous 
lines. Patients with oral mucositis were 
significantly more likely to have a more severe 
condition with a weight loss of more than 
5%.[5,8] In terms of medical costs, there is a 
significant difference between patients with 
mucositis and without mucositis. Patients 
without mucositis required an inpatient fee of 
approximately $3893 per chemotherapy cycle, 
with oral mucositis $6277 per cycle whereas 
those with oral and GI mucositis were $9132 per 
cycle. [3,4] 
So based on the above conditions, it 
seems that prevention of mucositis is 
important. Various attempts have been made, 
but until now they have not yielded satisfactory 
results. Based on the role of oxidants in the 
mucositis process, Vitamin E which is known to 
have antioxidant properties in the 
inflammatory [7,8] process is expected to prevent 
mucositis in solid tumor patients undergoing 
chemotherapy.  
M E T H O D S 
Study Design 
This study is a single blind clinical trial 
with random sampling which aims to 
determine the incidence of oral mucositis in 
NHL patients receiving chemotherapy. The 
research subjects were 62 NHL patients who 
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met the inclusion criteria. Subjects were 
divided randomly into 2 groups, namely the 
treatment group and the control group 
(placebo) each of 31 patients. The inclusion 
criteria were NHL patients who were 
undergoing chemotherapy, were over 16 years 
of age, were not experiencing mucositis, and 
were willing to sign an informed consent to 
participate in the study. 
Subsequently, subjects who met the 
inclusion criteria were subjected to an 
anamnesis regarding their main complaints, 
medical history and previous therapy as well as 
a general physical examination, including 
awareness, vital signs, examination of the head, 
neck, chest, lungs, heart, stomach, and 
extremities. Then the patients in the treatment 
group were given vitamin E and the placebo 
group was given placebo therapy for 7 days 
which was physically the same as vitamin E. On 
the 7th day of chemotherapy, the patients were 
examined to assess the incidence of oral 
mucositis and the degree of mucositis. This 
study has received approval from the Health 
Research Ethics Commission dr. Saiful Anwar by 
number 400/282/K.3/302/2019.   
Statistical analysis 
Statistical analysis using statistical 
tools, IBM Statistical Products and Service 
Solutions Statistics (SPSS) version 25.0 for 
Windows. Data were analyzed using Chi Square 
test and Mann Whitney test according to the 
type of data. 
R E S U L T S 
Characteristics of subjects 
The proportion of the incidence of oral 
mucositis between men and women was not 
significantly different, namely 26.2% in men 
and 25.0% in women. Based on age, it was 
found that the highest incidence of oral 
mucositis was in the age group over 46 years 
(61.3%), whereas proportionally the incidence 
of oral mucositis was higher in the 26-45 years 
age group than in the 45-45 years age group 
(46.7% vs 26.7%; p <0.05) (Table 1). 






 (+) (-)  
Sex  Male  31 11 42 (67.7) 
Female  16 4 20 (32.3) 
Age 
(range)  
16-25  2 0 2 (3.2) 
26-45   15 7 22 (35.5) 




CEOP 0 1 1 (1.6) 
CHOP 14 6 7 (35.5) 
COP 1 0 1 (1.6) 
RCEOP 7 0 7 (11.3) 
RCHOP 23 7 30 (48.4) 
RCOP 2 1 3 (4.8) 
* R, rituximab; C, cyclophosphamide; H, hydroxydaunorubicin 
(doxorubicin) hydrochloride; O, oncovin (vincristine); P, prednisone 
Table 2. incidence of Oral Mucositis between 
Placebo and Therapy Groups 
 Placebo 
group (n=31) 






(+) 11 (35.0) 4 (12.9) 0.038* 
(-)  20 (65.0) 27 (87.2)  
*Chi-Square test 
Table 3. The severity of oral mucositis between the 














0 20 (32.2) 27 (43,5)* 47 (75,8) 
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1 4 (6,5) 4 (6,5) 8 (12.9) 
2 4 (6,5) 0 (0) 4 (6.5) 
3 3 (4,8) 0 (0) 3 (4.8) 
*Chi-Square test 
Based on Table 3, it shows the 
incidence of oral mucositis was found in 15 
(24%) patients of the total patients who 
underwent chemotherapy. The highest degree 
of mucositis was grade 0 as much as 47 (75.8%) 
and the lowest degree of mucositis was grade 3 
as many as 8 patients (4.8%). In the vitamin E 
therapy group, the proportion of grade 0 oral 
mucositis was significantly different compared 
to the placebo group (43.5% vs 32.2%; p <0.05) 
and there was no grade 2 and 3 oral mucositis 
(Table 3). 
Table 4. Correlation between Vitamin E T herapy 

















Based on Table 4, there is a significant 
difference in the degree of mucositis in the 
placebo group compared to the treatment 
group (p=0.021).  
D I S C U S S I O N 
The age range of the subjects in this 
study was 18-79 years with the largest age being 
over 46 years. This is consistent with a study 
that reported the largest incidence of NHL was 
at the age of 35-65 years. [11,12] (Table 1). 
Based on data in the UK in 2012 the 
incidence of NHL ( Non-Hodgkin Lymphoma) 
increases with older age. The American Cancer 
Society in 2019 also stated that the risk of 
developing NHL increases at older people over 
65 years compared to younger ages.[13] 
Based on available evidence, it has 
been shown that an increased incidence of 
chemotherapy-induced mucositis in elderly 
patients is associated with changes that 
accumulate with time, affecting both genetic 
and environmental causes. The presence of 
prolonged exposure to carcinogens in the 
elderly and increased risk of epigenetic gene 
mutations, telomere dysfunction, limited 
replication potential, altered environment, 
apoptosis, all contribute to the changing 
environment leading to chemotherapy-
induced mucositis.[14] 
Other studies have also shown that the 
incidence of chemotherapy-induced oral 
mucositis is higher at older ages (over 45 years) 
compared to younger ages.[15] In accordance 
with the results of this study, the highest 
incidence of chemotherapy-induced oral 
mucositis was found at the age above 45 years 
or about 50% of the total sample. 
In this study, there were more male 
than female patients (61.7% vs 32.3%) (Table 
1). Sex differences in the incidence of NHL were 
related to differences in epidemiology, clinical 
features and response to therapy. The 
incidence of NHL in the last 20 years shows that 
the incidence rate for the male sex is 
significantly higher than that for the female 
gender. Clinical characteristics are also 
different, in women the predominant location 
of NHL in extra nodals such as mother, thyroid 
and respiratory system, while related to 
therapy response, in women the response to 
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therapy with anti-CD 20 or rituximab was better 
than men.[18]  
Chemotherapy-induced mucositis in 
this study was found to be more in male 
patients than female patients. Previous studies 
have shown that gender is considered to be a 
factor influencing the incidence of mucositis 
although some studies have shown conflicting 
results. 
The effect of sex hormones has been 
investigated in vitro and resulted in a theory 
about the direct effect of estrogen on the cell 
proliferation process or the effect on the anti-
tumor response on the female immune system 
is thought to be responsible for explaining the 
decrease in the incidence of chemotherapy-
induced mucositis in women.[20] Another 
mechanism thought to be related to the effects 
of estrogen is the immune response. The study 
found that 17β-estradiol spontaneously 
decreased the production of IL6 by MN cells 
resulting in lower levels of IL6. Meanwhile, high 
IL6 levels are associated with the incidence of 
chemotherapy-induced mucositis.[20] Estrogen 
exerts a protective effect by lowering IL6 
(Interleukin-6) levels. Immunological effects 
that are not directly related to sex hormones 
were also explored. Helper T cells are essential 
for the body's immune response. T Helper 1 
(TH1) cells secrete cytokines that promote 
cellular immunity to fight intracellular 
pathogens while T helper 2 cells (TH2) control 
humoral immunity by regulating antibody 
production. Unbalanced regulation and 
expression of cytokines TH1 and TH2 play an 
important role in the development of 
chemotherapy-induced mucositis.[23] Another 
proposed mechanism is through the direct 
effect of estrogen on all types of lymphocytes 
that express estrogen receptors. The 
mechanism of estrogen inhibition on cell 
proliferation is unclear, but it is thought to play 
a role in chemotherapy-induced mucositis.[24] 
Based on the information above, it can be 
concluded that the gender factor in the 
incidence of mucositis still causes controversy, 
so in this study gender cannot be ruled out as a 
confounding factor. 
Doxorubicin-based chemotherapy 
remains the gold standard of first-line NHL 
therapy. In this study the CHOP regimen was 
administered to 14 (22.5%) patients, whereas 
the COP regimen was administered to only 1 
(1.2%) patient. The LNH management 
guidelines recommend CHOP as the regimen of 
first choice in LNH patients. [35] 
Doxorubicin is a drug belonging to the 
anthracycline class that has the potential to 
cause chemotherapy-induced mucositis. There 
are two mechanisms of doxorubicin activity 
against cancer cells, the first is through the 
intercalation bond into DNA which interferes 
with the work of 2-topoisomerase which is 
useful in the DNA replication process and the 
second is through the formation of free radicals 
to damage cell membranes, DNA, and 
proteins.[26] Doxorubicin is oxidized to 
semiquinone, an unstable metabolite which is 
converted back to doxorubicin. This conversion 
process releases ROS (Reactive Oxygen 
Species) which can result in fat peroxidation 
and damage to membranes, DNA, oxidative 
stress, and triggers apoptosis from cells. Gene 
candidates that regulate this conversion 
process involve enzymes that can carry out 
oxidation reactions (NADH dehydrogenase, 
nitric oxide synthase, xanthine oxidase) and 
deactivate glutathione peroxidase, catalase, 
superoxide dismutase.[6] There is another 
possibility that doxorubicin can enter the 
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nucleus and interfere with 2-topoisomerase 
which results in DNA damage and cell death.[26] 
Doxorubicin is a cytostatic drug which 
also often causes serious side effects in the 
form of mucositis. Doxorubicin acts primarily at 
the DNA level by forming covalent bonds to DNA 
and is associated with increased apoptosis of 
actively multiplying cells which ultimately leads 
to inhibited proliferation of new mucosal cells. 
This condition supports the occurrence of 
mucositis due to chemotherapy in patients.[26] 
Another agent is Cyclophosphamide 
(CYC). Cyclophosphamide is a chemotherapy 
agent with alkylating activity related to 
nitrogen that binds to DNA and interferes with 
mitosis and cell replication. CYC targets rapidly 
dividing cells and is often used in antineoplastic 
management in the context of solid tumor and 
hematological malignancies. CYC has been 
shown to be effective in the treatment of 
lymphoma, leukemia, multiple myeloma, 
breast cancer, ovarian adenocarcinoma, retino-
blastoma, neuroblastoma, nephritic syndrome 
in children, and others. Cyclophosphamide also 
has immunosuppressive effects in addition to 
anti-mitotic and anti-replication effects. 
Specifically, CYC induces suppression of 
cellular and humoral immunity through its 
action on T and B cells. [32] The activity of 
cyclophosphamide as an immunosuppressant 
agent is derived from its ability to kill 
proliferating lymphocytes, including natural 
killer cells, T cells, and B cells, all of which are 
sensitive to cyclophosphamide.[32] 
Some other chemotherapy agents that 
have been shown to have high mucosal toxicity 
are daunorubicin, ara-C, etoposide, 
cyclophosphamide, doxorubicin, idarubicin 
and busulfan / melphalan.[32] 
Based on the results of this study, it was 
found that the regimen using doxorubicin 
caused the most chemotherapy-induced 
mucositis (CHOP and RCHOP) so it was 
suspected that doxorubicin might play an 
important role in the incidence of oral 
mucositis.  
Effect of Vitamin E on Chemotherapy-
Induced Mucositis 
Chemotherapy-induced oral mucositis 
is defined as the appearance of ulcerated 
lesions in the mouth area after chemotherapy. 
Oral mucositis appears on day 1-14, influenced 
by many factors including nutritional status, 
comorbidities such as metabolic diseases (DM, 
CKD), viral, bacterial and fungal infections. In 
this study patients with previous mucositis 
were excluded from the study. The examination 
of the incidence of mucositis which was 
checked on the 7th day of chemotherapy 
showed that the incidence of chemotherapy-
induced mucositis occurred on the 7th day of 
chemotherapy drug administration. This 
condition is in accordance with the theory of 
the nadir point of chemotherapy agents, 
namely the 7th day of chemotherapy agents at 
the lowest point of the immune system. usually 
characterized by the onset of neutropenia in 
the patient.[29] 
This study showed that the 
administration of vitamin E significantly 
reduced the incidence of chemotherapy-
induced oral mucositis in NHL patients 
undergoing chemotherapy (Table 2). The 
ability of vitamin E to protect epithelial cells 
thereby reducing the degree of mucositis is due 
to its ability to increase the order of the lipid 
structure of the cell membrane to become 
tighter. Free radicals make the membrane 
phospholipid its main target and in this case 
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vitamin E efficiently prevents the peroxidation 
of fat in the cell membrane. Therefore, vitamin 
E improves the quality of cell membrane 
recovery by preventing the formation of 
oxidized phospholipids that can interfere with 
the fusion of the cell membrane.[28] 
The effect of vitamin E on the degree of 
chemotherapy-induced mucositis 
The degree of chemotherapy-induced 
oral mucositis was higher in the placebo group 
than in the vitamin E group (Tables 3 and 4). 
This is similar to the study of alpha tocopherol 
administration in the incidence of 
chemotherapy-induced mucositis in patients 
where the results of the treatment group were 
lighter in degree than the placebo group. The 
study stated that patients in the placebo group 
had grade 1, 2, 3 and 4 mucositis, while the 
treatment group only experienced grade 1, 2 
and 3 mucositis without anyone getting grade 4 
mucositis.[26] 
Factors affecting the degree of 
chemotherapy-induced oral mucositis include 
complaints of pain in the oral cavity before 
chemotherapy and lack of attention to oral 
hygiene before, during and after 
chemotherapy. Additional risk factors are the 
type of cancer, the location of the cancer, the 
antineoplastic substance used, the dose, the 
administration schedule, the radiation area, 
and the patient's age.[30] 
As previously explained, vitamin E can 
act as an anti-oxidant or anti-inflammatory in 
chemotherapy-induced mucositis. One way to 
further explain whether the antioxidant 
mechanism underlying the decrease in the 
incidence of mucositis due to chemotherapy 
requires examination of the antioxidant 
marker, namely Malondialdehyde (MDA). MDA is 
the end product of lipid oxidation. High levels of 
MDA are influenced by levels of lipid 
peroxidation, which indirectly also indicates a 
high number of free radicals. Free radicals are 
highly reactive, can cause biochemical changes 
and damage various components of living cells 
such as proteins, lipids, carbohydrates, and the 
nucleus of the cell membrane which consists of 
lipid components.[35] 
Limitations of the study 
Some of the limitations of this study 
were the uneven proportion of patients based 
on age, type of chemotherapy and duration of 
chemotherapy for each subject so that they 
could not control for this as a confounding 
factor. Besides, adherence to taking vitamin E 
in the study subjects was only assessed based 
on anamnesis. 
C O N C L U S I O N 
Patients with NHL who are receiving 
chemotherapy, giving Vitamin E can prevent 
oral mucositis. Giving vitamin E can also reduce 
the degree of chemotherapy-induced oral 
mucositis. 
More specific research is needed 
regarding chemotherapy regimens and 
duration of chemotherapy on the incidence of 
chemotherapy-induced mucositis and further 
research related to the factors that influence 
the occurrence of chemotherapy-induced 
mucositis. 
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